Analyst Price Target is $10.25
▲ +428.35% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Aadi Bioscience in the last 3 months. The average price target is $10.25, with a high forecast of $36.00 and a low forecast of $1.50. The average price target represents a 428.35% upside from the last price of $1.94.
Current Consensus is
Hold
The current consensus among 5 investment analysts is to hold stock in Aadi Bioscience. This rating has held steady since August 2024, when it changed from a Moderate Buy consensus rating.
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Read More